The Goldman Sachs Group Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $51.00

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) had its price objective upped by The Goldman Sachs Group from $46.00 to $51.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a "neutral" rating on the stock. The Goldman Sachs Group's target price points to a potential upside of 7.01% from the company's previous close.

Several other research firms also recently issued reports on TARS. Oppenheimer boosted their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Guggenheim raised their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a report on Friday. Jefferies Financial Group boosted their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Finally, Barclays dropped their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $66.33.

Tarsus Pharmaceuticals Stock Up 0.6 %

Shares of Tarsus Pharmaceuticals stock traded up $0.30 during trading on Monday, hitting $47.66. 130,287 shares of the stock traded hands, compared to its average volume of 694,336. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market cap of $2.00 billion, a P/E ratio of -12.55 and a beta of 0.94. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The company has a fifty day moving average price of $47.94 and a two-hundred day moving average price of $48.90.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $78.34 million for the quarter, compared to the consensus estimate of $72.50 million. Equities research analysts predict that Tarsus Pharmaceuticals will post -3.17 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, General Counsel Bryan Wahl sold 3,341 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the sale, the general counsel now directly owns 58,057 shares of the company's stock, valued at approximately $2,687,458.53. The trade was a 5.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Dianne C. Whitfield sold 2,315 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $107,161.35. Following the transaction, the insider now owns 50,751 shares of the company's stock, valued at approximately $2,349,263.79. This trade represents a 4.36 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,542 shares of company stock worth $1,581,173. Company insiders own 8.25% of the company's stock.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Crowley Wealth Management Inc. bought a new position in Tarsus Pharmaceuticals in the fourth quarter valued at $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $44,000. R Squared Ltd bought a new stake in Tarsus Pharmaceuticals during the fourth quarter worth about $53,000. Amalgamated Bank boosted its position in Tarsus Pharmaceuticals by 30.1% during the first quarter. Amalgamated Bank now owns 1,274 shares of the company's stock valued at $65,000 after purchasing an additional 295 shares during the last quarter. Finally, Quarry LP bought a new position in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $166,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.